公开(公告)号：US12188927B2

公开(公告)日：2025-01-07

申请号：US18630584

申请日：2024-04-09

Applicant: Horizon Therapeutics USA, Inc.

Inventor： Theresa Rosario-Jansen ,  David Erick Wright

IPC: C12Q1/62 ,  A61K9/00 ,  A61K38/44 ,  A61K47/60 ,  A61P19/02 ,  G01N33/53 ,  G01N33/68

Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

公开(公告)号：US11639927B2

公开(公告)日：2023-05-02

申请号：US17036110

申请日：2020-09-29

Applicant: Horizon Therapeutics USA, Inc.

Inventor： Theresa Rosario-Jansen ,  David Erick Wright

IPC: C12Q1/62 ,  G01N33/53 ,  G01N33/68 ,  C12N9/02 ,  A61K47/60 ,  A61P19/02 ,  A61K9/00 ,  A61K38/44

Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

公开(公告)号：US11982670B2

公开(公告)日：2024-05-14

申请号：US18104578

申请日：2023-02-01

Applicant: Horizon Therapeutics USA, Inc.

Inventor： Theresa Rosario-Jansen ,  David Erick Wright

IPC: G01N33/53 ,  A61K9/00 ,  A61K38/44 ,  A61K47/60 ,  A61P19/02 ,  A61P19/06 ,  G01N33/68

CPC classification number: G01N33/5308 ,  A61K9/0019 ,  A61K38/44 ,  A61K47/60 ,  A61P19/02 ,  C12Y107/03003 ,  G01N33/6893 ,  G01N2333/90694 ,  G01N2800/107 ,  G01N2800/52 ,  G01N2800/56

Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

公开(公告)号：US11598767B2

公开(公告)日：2023-03-07

申请号：US17934119

申请日：2022-09-21

Applicant: Horizon Therapeutics USA, Inc.

Inventor： Theresa Rosario-Jansen ,  David Erick Wright

IPC: G01N33/53 ,  G01N33/68 ,  A61K47/60 ,  A61P19/02 ,  A61K9/00 ,  A61K38/44

Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

公开(公告)号：US20230028134A1

公开(公告)日：2023-01-26

申请号：US17934119

申请日：2022-09-21

Applicant: Horizon Therapeutics USA, Inc.

Inventor： Theresa Rosario-Jansen ,  David Erick Wright

IPC: G01N33/53 ,  A61K38/44 ,  A61K47/60 ,  A61K9/00 ,  A61P19/02 ,  G01N33/68

Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.